Frazier Elfaridah P, Schneider Tim, Michel Martin C
Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Amsterdam, The Netherlands.
Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):300-9. doi: 10.1007/s00210-006-0077-y. Epub 2006 May 31.
beta-Adrenoceptors mediate urinary bladder relaxation, and gender, age and hypertension have been linked to bladder dysfunction. Therefore, we have studied whether any of these factors affects the ability of beta-adrenoceptor agonists to relax rat bladder detrusor muscle in vitro. For this purpose we have compared male and female Wistar rats, young and old male Wistar rats, and male normotensive and spontaneously hypertensive rats (SHR). Comparisons were done using KCl-precontracted bladder strips (length about 15-20 mm) and the endogenous agonist noradrenaline, the synthetic non-subtype-selective agonist isoprenaline, and the prototypical beta(3)-adrenoceptor agonists BRL 37,344 and CGP 12,177. While all agonists yielded numerically weaker relaxation in female as compared to male rats (for example for noradrenaline E(max) 40+/-4% vs 53+/-6% relaxation, pEC(50) 5.41+/-0.13 vs 5.60+/-0.14), this difference reached statistical significance only for the weak partial agonist CGP 12,177. Responses to all agonists were attenuated in old as compared to young rats, largely due to a reduced maximum effect, although the difference did not reach statistical significance for isoprenaline. The maximum relaxation responses to noradrenaline and isoprenaline were significantly lower in SHR than in normotensive rats, but both strains exhibited similar responses to the partial agonist BRL 37,344. We conclude that factors associated with bladder dysfunction, such as gender, age and hypertension, can be associated with impaired beta-adrenoceptor-mediated bladder relaxation. However, these alterations are not always consistent across various agonists, and the extent of the differences can be small. Therefore, we propose that beta-adrenoceptor dysfunction may contribute to the pathophysiology of such conditions, but is unlikely to be the only or even the major factor in this regard. We speculate that beta-adrenoceptor agonists may be effective in the treatment of bladder dysfunction under all of these conditions.
β-肾上腺素能受体介导膀胱舒张,性别、年龄和高血压与膀胱功能障碍有关。因此,我们研究了这些因素是否会影响β-肾上腺素能受体激动剂在体外舒张大鼠膀胱逼尿肌的能力。为此,我们比较了雄性和雌性Wistar大鼠、年轻和年老雄性Wistar大鼠,以及雄性正常血压大鼠和自发性高血压大鼠(SHR)。使用氯化钾预收缩的膀胱条(长度约15 - 20毫米)以及内源性激动剂去甲肾上腺素、合成的非亚型选择性激动剂异丙肾上腺素和典型的β(3)-肾上腺素能受体激动剂BRL 37,344和CGP 12,177进行比较。与雄性大鼠相比,所有激动剂在雌性大鼠中产生的舒张数值均较弱(例如,去甲肾上腺素的E(max)为40±4%的舒张与53±6%的舒张,pEC(50)为5.41±0.13与5.60±0.14),但这种差异仅在弱部分激动剂CGP 12,177时达到统计学显著性。与年轻大鼠相比,老年大鼠对所有激动剂的反应均减弱,这主要是由于最大效应降低,尽管异丙肾上腺素的差异未达到统计学显著性。SHR对去甲肾上腺素和异丙肾上腺素的最大舒张反应显著低于正常血压大鼠,但两种品系对部分激动剂BRL 37,344表现出相似的反应。我们得出结论,与膀胱功能障碍相关的因素,如性别、年龄和高血压,可能与β-肾上腺素能受体介导的膀胱舒张受损有关。然而,这些改变在不同激动剂之间并不总是一致的,且差异程度可能较小。因此,我们认为β-肾上腺素能受体功能障碍可能促成这些病症的病理生理学,但在这方面不太可能是唯一甚至主要因素。我们推测β-肾上腺素能受体激动剂在所有这些情况下可能对膀胱功能障碍的治疗有效。